Shares of AstraZeneca Pharma India Ltd. rallied 12%, reaching a day’s high of Rs 7,598 on 24th September, after the company announced that it had received approval from the Central Drugs Standard Control Organisation (CDSCO) to import and distribute durvalumab (Imfinzi) for an additional indication in India.

AstraZeneca Pharma India received approval from the Central Drugs Standard Control Organisation to import and sell durvalumab (Imfinzi) in 120 mg/2.4 mL and 500 mg/10 mL infusion doses.

The approval allows durvalumab to be used with chemotherapy as a pre-surgery treatment and as a post-surgery monotherapy for larger tumours and node-positive NSCLC cases.

Durvalumab (Imfinzi), combined with chemotherapy as a pre-surgery treatment and followed by Imfinzi monotherapy post-surgery, is indicated for patients with resectable NSCLC (tumours 4 cm and/or node-positive) without EGFR mutations or ALK rearrangements.

AstraZeneca Pharma India stated that receiving approval allows for the launch of Durvalumab in India for this additional indication, pending any further required statutory clearances.

So far in 2024, the stock has surged by almost 34%. Today, the company’s market capitalisation rose significantly to Rs 18,936 crore.

At 10:54 AM, the shares of AstraZeneca Pharma were trading 12.11% higher at Rs 7,565 on NSE.

Discover the next big investment! Unicorn Signals’ IPO screener helps you identify promising initial public offerings. Download Unicorn Signals and get ahead of the curve! Sign Up Now & Find Your Next IPO Gem!